SCHEMBL30002655

SCHEMBL30002655

O=C(O)Cc1cc2ccc(O)cc2oc1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.57
AKR1B1 P15121 2/20 0.56
LCK P06239 1/20 0.56
FYN P06241 1/20 0.56
GRB2 P62993 1/20 0.56
HSD17B3 P37058 1/20 0.55
MIF P14174 8/20 0.55
KDM4E B2RXH2 3/20 0.55
MEN1 O00255 3/20 0.55
GLA P06280 3/20 0.55
GAA P10253 3/20 0.55
KMT2A Q03164 3/20 0.55
S1PR4 O95977 2/20 0.55
MAPT P10636 2/20 0.55
S1PR1 P21453 2/20 0.55
NPC1 O15118 2/20 0.54
ALDH1A1 P00352 3/20 0.54
HPGD P15428 3/20 0.54
ESR2 Q92731 1/20 0.53
CA9 Q16790 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2274941 1.00 POLB (0.57) POLBAKR1B1LCKFYNGRB2
SCHEMBL9436016 0.85 KDM4E (0.54) POLBAKR1B1HSD17B3MIFKDM4E
SCHEMBL11128154 0.83 NPC1 (0.55) HSD17B3MIFMEN1KMT2AMAPT
SCHEMBL29066603 0.82 ESR2 (0.61) POLBAKR1B1HSD17B3MIFKDM4E
SCHEMBL220708 0.82 HSD17B3 (0.65) POLBAKR1B1HSD17B3MIFKDM4E
SCHEMBL30405545 0.82 HSD17B3 (0.65) POLBAKR1B1HSD17B3MIFKDM4E
SCHEMBL10845026 0.82 CA12 (0.50) POLBAKR1B1MIFKDM4EMEN1
SCHEMBL6037595 0.81 POLB (0.59) POLBAKR1B1HSD17B3MIFKDM4E
SCHEMBL2403666 0.81 RAB9A (0.59) POLBAKR1B1KDM4EMEN1KMT2A
SCHEMBL28164061 0.81 POLB (0.59) POLBAKR1B1HSD17B3MIFKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719450-A2 MODIFIED CAVEOLIN-1 PEPTIDE FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF Rein Therapeutics, Inc. (US) 2026-04-08 EP disclosed
WO-2024249565-A2 MODIFIED CAVEOLIN-1 PEPTIDE FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF LUNG THERAPEUTICS, LLC (US) 2024-12-05 WO disclosed
WO-2023154916-A2 COMPOSITIONS AND METHODS FOR TREATING INFECTIOUS DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-17 WO disclosed
US-20230212223-A1 MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSIS LUNG THERAPEUTICS, INC. (US) 2023-07-06 US disclosed
EP-4168031-A2 MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF PATHOGEN-INDUCED LUNG INJURY Lung Therapeutics, Inc. (US) 2023-04-26 EP disclosed
WO-2022217037-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC LUNG DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-10-13 WO disclosed